Aidee Health

Our Moonshot

Within five years, Aidee Health will become the standard-of-care for blood pressure diagnosis and follow-up.
We are transforming how hypertension is diagnosed and managed with the first clinical-grade, cuffless wearable that provides continuous, comfortable, and accurate 24-hour blood pressure monitoring. Our flagship product is designed to redefine ABPM and unlock earlier, smarter hypertension treatment.

The Problem

Hypertension is the world’s leading cause of premature death. It affects over 1.3 billion people globally, yet 46% of cases remain undiagnosed leading to >10M lives lost every year. In-office and home-based measurements frequently fail due to variability, “white coat” effects, and poor patient compliance. The current diagnostic gold standard — 24h Ambulatory Blood Pressure Monitoring (ABPM) — is accurate, but relies on cuff-based devices that are painful, disruptive, and often rejected by patients. This leads to underuse and delayed diagnosis, increasing the risk of stroke, heart failure, and kidney disease.

Our Solution: Aidee EmBody

A non-intrusive, cuffless, upper-arm wearable device for continuous blood pressure monitoring, to be validated for medical use and built with advanced ML and sensor technology.

• Worn on the upper arm — the clinically preferred site — for optimal signal accuracy
• Cuffless, 24-hour continuous monitoring, with BP readings every 15-60 seconds
• 1200+ sensor data points per second, enabling high-resolution BP curves
• Machine learning algorithms trained with clinical-grade datasets
• Optional multi-lead ECG functionality for expanded cardiovascular assessment
• Multisensor vital tracking: BP, HR, HRV, SpO₂, sleep stage, temperature, respiratory rate & more
• Proven sleep-friendly and pain-free, unlike traditional inflatable cuff devices
• Data is synced to a secure cloud platform, with clinician access via a dedicated PC interface

Market Opportunity

• Over 56 million adults in Europe remain undiagnosed with hypertension
• ABPM market projected to reach €3.6B by 2030
• Clinical demand for comfortable, accurate, wearable alternatives is surging
• No competing cuffless solution has passed clinical validation requirements — we are on track to be first

Our Unique Positioning

Aidee is not just another wearable — it’s a medical breakthrough.

• 13+ years of R&D with SINTEF and Oslo University Hospital
• >600 patients tested, 10+ clinical studies, 5+ peer-reviewed publications
• First cuffless device capable of accurate nighttime monitoring
• Designed for general practice and hospital settings
• Backed by key opinion leaders and supported by a robust partner network
• Compliant with ISO 13485 and ISO 27001

Go-to-Market, Business Model

This information is provided to investors on request. 

Financial Overview

Financial forecasts and roll-out strategy is provided to investors on request

• Currently raising €3M with closing by EOY 2025
• Anticipated follow-on capital requirement: €3.5M–€7.2M

What We’re Looking For 

• Investors (medtech-focused VCs, family offices, health impact funds, CVCs)
• Distributors across the EU, UK, and US
• Hospitals and clinicians to support clinical validation and early adoption
• Regulatory and reimbursement advisors
• AI/ML experts in physiological data and wearable technologies

About Us

Aidee Health is a Norwegian medtech company spun out from SINTEF and Datek in 2021. We are a team of 17 cross-disciplinary experts in hardware, software, clinical research, regulatory strategy, and AI. Aidee is ISO 13485 and ISO 27001 compliant. Our work has been funded by the Norwegian Research Council and Innvation Norway.

Visit us at aidee.io | Contact: hello@aidee.io